GLP-1s have been linked to a range of side effects, with the most common including gastrointestinal problems such as nausea, vomiting, diarrhea and constipation
Beyond that, a head-to-head comparison from the SURMOUNT-5 trial illustrates the difference clearly: Participants taking tirzepatide lost an average of 20.2% of their body weight compared to 13.7% with semaglutide
01Keep Protein, Water, and Hot-Flash Notes in One Timeline Menopause can make the day feel harder to read before GLP-1 is even added
B., Milavic, M., Sikiric, S., Stilinovic, I., Simeon, P., Knezevic, M., Kolak, T., Tepes, M., Simonji, K., Strbe, S., Gabaj, N
In another study, an 84-week open-label trial with about 800 participants, people taking CagriSema had an average of 23% weight loss versus about 25 to 26% for tirzepatide (Zepbound) at the highest dose
Strengthening these structures reduces load on the compromised rotator cuff and supports recovery